Aytu Biopharma vs Journey Medical
Journey Medical reported revenue of $62 million in fiscal 2025, about the same as Aytu Biopharma's $58 million in fiscal 2026. Aytu Biopharma's revenue fell 13.3% in its latest year, and Journey Medical's grew 10.2%. Aytu Biopharma had an operating margin of -14.4%, against -13.2% at Journey Medical. Their fiscal years end in different months (June 30 and December 31), so the periods don't line up exactly.
Side by side
| Aytu Biopharma | Journey Medical | |
|---|---|---|
| Latest fiscal year | FY2026, Jun 30, 2026 | FY2025, Dec 31, 2025 |
| Revenue | $58M | $62M |
| Revenue growth | −13.3% | 10.2% |
| Revenue growth a year, last 5 years | −2.6% | 6.8% |
| Gross margin | 64.0% | 66.2% |
| Operating margin | −14.4% | −13.2% |
| Net margin | −24.8% | −18.5% |
| Free cash flow | $3M | — |
| Free cash flow margin | 5.7% | — |
| Return on capital | — | −22.4% |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | 96.2% | 19.9% |
| Last close | $2.66 | $3.55 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | — | — |
| Piotroski F-score | — | 5 of 9 |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
Aytu BiopharmaJourney Medical
Operating margin
Percent of revenue
Aytu BiopharmaJourney Medical
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Aytu BiopharmaJourney Medical
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Aytu Biopharma and Journey Medical pages.